Purchase this article with an account.
A. Robin, T. Maalouf, J. George, K. Angioi; Intravitreal Ranibizumab Outcomes in the Exsudative Age Related Macular Degeneration Treatment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4951.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess intravitreal (IVT) Ranibizumab effects on visual acuity (VA) and central macular thickness in exsudative age-related macular degeneration (AMD)
Retrospective, monocentric study of a consecutive cohort treated with intravitreal Ranibizumab for exsudative AMD for which VA (Snellen chart) and central macular thickness (measured by OCT) were followed.
62 patients (65 treated eyes) were included, mean age was 65 +/- 8 years old, 57% were women. The mean number of IVT injection was 3+/-1.7. Clinical examination was performed at 1 month and every 3 months with an average follow-up was 12 months. Initial VA was 20/80 (mean log MAR = 0.705 +/- 0.348) and remained unchanged at follow-up (20/80, mean log MAR = 0,770 +/- 0,425; p = 0.41). By contrast, a statistically significant decrease of the central macular thickness was observed (334.87 +/- 136.31 vs 251.85 +/- 139.73 micrometers; p<0.001). No induced-IVT side effects were reported.
The main randomized clinical trials (MARINA, ANCHOR and PrONTO) found VA improvement that we did not reach in our cohort with only VA stabilization. This could be explain by the far less number of IVT performed in our population. Conversely, our results compared favorably for the evolution of the retinal thickness. Our present results suggest that a more pronounced effect on VA could be achieved with a more sustained follow-up with repeated IVT injection if needed in order to improve visual prognosis.
This PDF is available to Subscribers Only